PHARMACORP RX INC (PCRX.CA) Fundamental Analysis & Valuation

TSX-V:PCRX • CA71714X1050

Current stock price

0.45 CAD
+0.01 (+2.27%)
Last:

This PCRX.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. PCRX.CA Profitability Analysis

1.1 Basic Checks

  • PCRX had negative earnings in the past year.
  • PCRX had a positive operating cash flow in the past year.
PCRX.CA Yearly Net Income VS EBIT VS OCF VS FCFPCRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -500K -1M -1.5M

1.2 Ratios

  • PCRX has a Return On Assets of 0.48%. This is amonst the worse of the industry: PCRX underperforms 81.25% of its industry peers.
  • With a Return On Equity value of 0.63%, PCRX is not doing good in the industry: 81.25% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA 0.48%
ROE 0.63%
ROIC N/A
ROA(3y)-14.02%
ROA(5y)N/A
ROE(3y)-14.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PCRX.CA Yearly ROA, ROE, ROICPCRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -5 -10 -15 -20

1.3 Margins

  • PCRX has a worse Profit Margin (1.08%) than 75.00% of its industry peers.
  • PCRX's Gross Margin of 39.77% is amongst the best of the industry. PCRX outperforms 87.50% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 1.08%
GM 39.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCRX.CA Yearly Profit, Operating, Gross MarginsPCRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 20 -20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. PCRX.CA Health Analysis

2.1 Basic Checks

  • PCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PCRX has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, PCRX has a worse debt to assets ratio.
PCRX.CA Yearly Shares OutstandingPCRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M 80M 100M
PCRX.CA Yearly Total Debt VS Total AssetsPCRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • An Altman-Z score of 5.32 indicates that PCRX is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 5.32, PCRX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • The Debt to FCF ratio of PCRX is 2.81, which is a good value as it means it would take PCRX, 2.81 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of PCRX (2.81) is better than 100.00% of its industry peers.
  • A Debt/Equity ratio of 0.13 indicates that PCRX is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.13, PCRX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF 2.81
Altman-Z 5.32
ROIC/WACCN/A
WACC7.9%
PCRX.CA Yearly LT Debt VS Equity VS FCFPCRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

  • PCRX has a Current Ratio of 2.53. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 2.53, PCRX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • A Quick Ratio of 1.79 indicates that PCRX should not have too much problems paying its short term obligations.
  • PCRX has a better Quick ratio (1.79) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.53
Quick Ratio 1.79
PCRX.CA Yearly Current Assets VS Current LiabilitesPCRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. PCRX.CA Growth Analysis

3.1 Past

  • PCRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.98%.
EPS 1Y (TTM)-5.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%334.83%

3.2 Future

  • The Earnings Per Share is expected to grow by 64.40% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 137.64% on average over the next years. This is a very strong growth
EPS Next Y100%
EPS Next 2Y79.49%
EPS Next 3Y64.4%
EPS Next 5YN/A
Revenue Next Year257.94%
Revenue Next 2Y205.97%
Revenue Next 3Y137.64%
Revenue Next 5YN/A

3.3 Evolution

PCRX.CA Yearly Revenue VS EstimatesPCRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 20M 40M 60M
PCRX.CA Yearly EPS VS EstimatesPCRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2026 2027 0.01 0.02 0.03

More info and screens

Find the best growth stocksShow best growing peers

2

4. PCRX.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Forward Earnings ratio is 29.70, which means the current valuation is very expensive for PCRX.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of PCRX indicates a slightly more expensive valuation: PCRX is more expensive than 75.00% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of PCRX to the average of the S&P500 Index (22.51), we can say PCRX is valued slightly more expensively.
Industry RankSector Rank
PE N/A
Fwd PE 29.7
PCRX.CA Price Earnings VS Forward Price EarningsPCRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PCRX is valued more expensive than 93.75% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of PCRX indicates a slightly more expensive valuation: PCRX is more expensive than 75.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 50.89
EV/EBITDA 141.95
PCRX.CA Per share dataPCRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.05 0.1 0.15

4.3 Compensation for Growth

  • PCRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as PCRX's earnings are expected to grow with 64.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y79.49%
EPS Next 3Y64.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PCRX.CA Dividend Analysis

5.1 Amount

  • PCRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PCRX.CA Fundamentals: All Metrics, Ratios and Statistics

PHARMACORP RX INC

TSX-V:PCRX (3/26/2026, 7:00:00 PM)

0.45

+0.01 (+2.27%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)11-29
Earnings (Next)04-20
Inst Owners9.84%
Inst Owner ChangeN/A
Ins Owners10.67%
Ins Owner ChangeN/A
Market Cap78.34M
Revenue(TTM)17.60M
Net Income(TTM)189.60K
Analysts80
Price Target0.59 (31.11%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.54%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 29.7
P/S 4.45
P/FCF 50.89
P/OCF 48.73
P/B 2.61
P/tB 9.8
EV/EBITDA 141.95
EPS(TTM)0
EYN/A
EPS(NY)0.02
Fwd EY3.37%
FCF(TTM)0.01
FCFY1.96%
OCF(TTM)0.01
OCFY2.05%
SpS0.1
BVpS0.17
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.48%
ROE 0.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1.08%
GM 39.77%
FCFM 8.74%
ROA(3y)-14.02%
ROA(5y)N/A
ROE(3y)-14.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF 2.81
Debt/EBITDA 7
Cap/Depr 8.65%
Cap/Sales 0.39%
Interest Coverage N/A
Cash Conversion 293.95%
Profit Quality 811.87%
Current Ratio 2.53
Quick Ratio 1.79
Altman-Z 5.32
F-Score6
WACC7.9%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.14%
EPS Next Y100%
EPS Next 2Y79.49%
EPS Next 3Y64.4%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%334.83%
Revenue Next Year257.94%
Revenue Next 2Y205.97%
Revenue Next 3Y137.64%
Revenue Next 5YN/A
EBIT growth 1Y-174.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year144.45%
EBIT Next 3Y111.82%
EBIT Next 5YN/A
FCF growth 1Y122.73%
FCF growth 3Y518.15%
FCF growth 5YN/A
OCF growth 1Y124.06%
OCF growth 3Y529.96%
OCF growth 5YN/A

PHARMACORP RX INC / PCRX.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PHARMACORP RX INC (PCRX.CA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PCRX.CA.


What is the valuation status for PCRX stock?

ChartMill assigns a valuation rating of 2 / 10 to PHARMACORP RX INC (PCRX.CA). This can be considered as Overvalued.


How profitable is PHARMACORP RX INC (PCRX.CA) stock?

PHARMACORP RX INC (PCRX.CA) has a profitability rating of 1 / 10.